Form 4: AKAM Director Purchased 3,000 Shares, Weighted Avg $72.299
Rhea-AI Filing Summary
Daniel Hesse, a director of Akamai Technologies, reported the purchase of 3,000 shares of Akamai common stock on 08/11/2025 at a weighted-average price of $72.299. The filing notes the shares were acquired in multiple transactions with prices ranging from $72.05 to $72.72 and offers to provide per-trade detail on request.
Following the purchases, Mr. Hesse beneficially owned 21,387 shares on a direct basis. The Form 4 discloses only non-derivative purchases and includes a power-of-attorney signature; no dispositions or derivative transactions are reported in this filing.
Positive
- None.
Negative
- None.
Insights
TL;DR: Director purchased 3,000 Akamai shares at a weighted-average $72.299; routine insider buy with limited market impact.
The Form 4 shows a straightforward non-derivative acquisition: 3,000 common shares acquired on 08/11/2025 at a reported weighted-average price of $72.299, with an indicated per-trade range of $72.05–$72.72. Beneficial ownership after the transaction is listed as 21,387 shares (direct). No option or derivative activity is reported. From a market perspective this is a clear insider purchase disclosure but, based on disclosed size alone, it is not presented as materially transformative to the company’s capital structure.
TL;DR: Form 4 appears properly completed; purchase is disclosed with a clarifying footnote and executed via power of attorney.
The filing includes the customary explanatory footnote noting the weighted-average price and per-trade price range, which improves transparency about how the reported price was calculated. The report is signed by a power of attorney, and Table II (derivatives) is empty, indicating no related derivative activity. The disclosure meets routine Section 16 reporting expectations and contains the primary facts investors rely on for insider-trade transparency.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 3,000 | $72.299 | $217K |
Footnotes (1)
- [object Object]
FAQ
What did Daniel Hesse report on the Form 4 for AKAM?
What price range covered the reported purchases?
Were any derivatives or option transactions reported for AKAM in this filing?
Who signed the Form 4 for Daniel Hesse?